• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    8/2/24 9:00:00 AM ET
    $CLDI
    $GP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Construction/Ag Equipment/Trucks
    Consumer Discretionary
    Get the next $CLDI alert in real time by email

    ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

    Access the interviews in their entirety at:

    • GreenPower Motor: https://www.redchip.com/assets/access/gp_access

    • Calidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_access

    In an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. GreenPower is a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector. The Company has established a solid track record of sales growth, including more than 700 EV Stars, low-floor transit buses and school buses delivered to date, and maintains a significant order book that which can be satisfied with existing production capacity at its California and West Virginia manufacturing facilities and through contract manufacturing. GreenPower's competitive positioning, solid sales trajectory, accomplished leadership and favorable market dynamics underscore its potential for sustained growth and value creation in the rapidly evolving EV industry.

    Allan Camaisa, CEO of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Calidi is at the forefront of oncolytic virotherapy (OV), a promising multi-billion-dollar area in cancer treatment. Calidi is pioneering the development of both systemic and localized OVs, leveraging engineered viruses to target and destroy cancer cells while arming the immune system for a comprehensive attack on tumors. Calidi's cell-based technologies uniquely protect OVs from immune system elimination, ensuring higher efficacy and opening the tumor microenvironment to treatment. This approach has shown promising efficacy in initial studies, while their breakthrough IV-based technology and direct tumor administration methods differentiate them within the oncology field.

    About GreenPower Motor Company, Inc.

    GreenPower designs, builds and distributes a full suite of high-floor and low-floor all-electric medium and heavy-duty vehicles, including transit buses, school buses, shuttles, cargo vans and a cab and chassis. GreenPower employs a clean-sheet design to manufacture all-electric vehicles that are purpose-built to be battery powered with zero emissions while integrating global suppliers for key components. This OEM platform allows GreenPower to meet the specifications of various operators while providing standard parts for ease of maintenance and accessibility for warranty requirements. GreenPower was founded in Vancouver, Canada with primary operational facilities in southern California. Listed on the Toronto exchange since November 2015, GreenPower completed its U.S. IPO and NASDAQ listing in August 2020. For further information go to www.greenpowermotor.com.

    About Calidi Biotherapeutics

    Calidi Biotherapeutics (NYSE:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

    About RedChip Companies

    RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

    To learn more about RedChip's products and services, please visit:

    https://www.redchip.com/corporate/investor_relations

    "Discovering Tomorrow's Blue Chips Today"™

    Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/

    Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies

    Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/

    Follow RedChip on Twitter: https://twitter.com/RedChip

    Follow RedChip on YouTube: https://www.youtube.com/@redchip

    Follow RedChip on Rumble: https://rumble.com/c/c-3068340

    Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

    Contact:

    Dave Gentry
    RedChip Companies Inc.
    1-407-644-4256
    [email protected]

    SOURCE: RedChip



    View the original press release on accesswire.com

    Get the next $CLDI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLDI
    $GP

    CompanyDatePrice TargetRatingAnalyst
    Calidi Biotherapeutics Inc.
    $CLDI
    11/22/2023$11.00Buy
    H.C. Wainwright
    Calidi Biotherapeutics Inc.
    $CLDI
    10/9/2023$9.00Outperform
    Robert W. Baird
    GreenPower Motor Company Inc.
    $GP
    2/15/2022$13.00Neutral → Buy
    ROTH Capital
    GreenPower Motor Company Inc.
    $GP
    11/15/2021$32.00 → $13.00Buy → Neutral
    ROTH Capital
    More analyst ratings

    $CLDI
    $GP
    SEC Filings

    View All

    SEC Form 6-K filed by GreenPower Motor Company Inc.

    6-K - GREENPOWER MOTOR Co INC. (0001584547) (Filer)

    8/18/25 9:49:38 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    SEC Form S-1 filed by Calidi Biotherapeutics Inc.

    S-1 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    8/15/25 5:21:26 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Calidi Biotherapeutics Inc.

    SCHEDULE 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    8/14/25 9:05:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Leftwich Scott

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:54 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Peoples George

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:56 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Schoeneck James A

    4 - Calidi Biotherapeutics, Inc. (0001855485) (Issuer)

    7/15/25 8:42:59 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Calidi Biotherapeutics with a rating of Buy and set a new price target of $11.00

    11/22/23 7:15:52 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

    Robert W. Baird initiated coverage of Calidi Biotherapeutics with a rating of Outperform and set a new price target of $9.00

    10/9/23 7:23:07 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GreenPower Motor upgraded by ROTH Capital with a new price target

    ROTH Capital upgraded GreenPower Motor from Neutral to Buy and set a new price target of $13.00

    2/15/22 8:52:35 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    $CLDI
    $GP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

    SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the pricing of an underwritten public offering for gross proceeds of $6 million prior to deducting underwriting commissions and offering expenses. "We are extremely pleased to have priced this transaction despite difficult market conditions," said Eric Poma, Chief Executive Officer of Calidi Biotherapeutics. "This transaction included participation from current shareholders and new investors as we

    8/20/25 9:15:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GreenPower Signs Contract for More Than $5 Million with State of New Mexico for All-Electric School Bus Pilot Program

    SANTA FE, N.M., Aug. 4, 2025 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ:GP) (TSXV:GPV) ("GreenPower"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today announced it has signed a contract with the state of New Mexico to implement an all-electric school bus pilot project. The contract is the result of an award made by the state under an RFP published in May. The two-year pilot project will deploy three GreenPo

    8/4/25 8:30:00 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    $CLDI
    $GP
    Leadership Updates

    Live Leadership Updates

    View All

    GreenPower Announces Results of Annual General and Special Meeting and Appointment of Officers

    VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ:GP) (TSXV:GPV) (the "Company"), a leading manufacturer and distributor of purpose-built, all-electric, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, announces the results of the Annual General and Special Meeting (AGM) that was held today. The shareholders elected all of management's director nominees being Mark Achtemichuk, Fraser Atkinson, Malcolm Clay, Sebastian Giordano, David Richardson and Brendan Riley.

    5/23/25 7:00:00 PM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights

    Bolstered management team with hires of Chief Executive Officer and Chief Medical Officer with deep biopharmaceutical experienceAnnounced selection of IL15-superagonist as first payload to be delivered into tumors with Calidi's first lead candidate using its systemic antitumor virotherapy platform, Redtail; IND filing expected in the second half of 2026 IND cleared by FDA for CLD-201 clinical trial SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the potential to deliver genetic payloads, today reported its first quarter 2025

    5/14/25 4:30:00 PM ET
    $CLDI
    $MTEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

    SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that in connection with the appointment of Eric Poma, Ph.D. as Chief Executive Officer , the Company's Compensation Committee and the Board of Directors has approved the grant of an inducement non-qualified stock option for Dr. Poma for the purchase of 726,412 shares with an exercise price of $0.469, which was the closing price of the Company's common stock on April 22, 2025, the date of grant (the "Stock Options"). The Stock Options vest over four years with 25% of the Stoc

    4/25/25 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CLDI
    $GP
    Financials

    Live finance-specific insights

    View All

    Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

    Presented preclinical data at the American Society of Clinical Oncology (ASCO) on CLD-401 demonstrating biological efficacy IL-15 superagonist delivery to metastatic tumor sites and reduced immune clearance through engineered CD55 membrane expression; IND filing expected by the end of 2026Received FDA Fast Track Designation for CLD-201, a first-in-class stem-cell loaded intratumoral viral therapy for the treatment of patients with soft tissue sarcomaRaised $4.6 million gross proceeds through a warrant inducement offering with existing investors that further strengthens the company's balance sheet and extends its runway SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics

    8/8/25 4:15:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

    Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial to treat multiple solid tumorsCommencement of recruitment for Phase 1 trial in patients with newly diagnosed high-grade glioma at Northwestern University hospital14 patients enrolled in Phase 1 trial conducted by City of Hope to treat recurrent high-grade glioma SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and fu

    3/31/25 4:10:00 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    GreenPower Provides Business Update and Reports Third Quarter Fiscal 2025 Results

    Shareholder Call Scheduled for February 18, 2025 at 9:30 a.m. EST/6:30 a.m. PST VANCOUVER, BC, Feb. 14, 2025 /PRNewswire/ -- GreenPower Motor Company Inc. (NASDAQ:GP) (TSXV:GPV) ("GreenPower" and the "Company"), a leading manufacturer and distributor of all-electric, purpose-built, zero-emission medium and heavy-duty vehicles serving the cargo and delivery market, shuttle and transit space and school bus sector, today reported its third quarter fiscal year 2025 results and provided an update on its manufacturing operations. "GreenPower's improved third-quarter performance, wit

    2/14/25 6:54:00 PM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary

    $CLDI
    $GP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

    SC 13G/A - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    11/14/24 2:05:25 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

    SC 13G - Calidi Biotherapeutics, Inc. (0001855485) (Subject)

    9/11/24 4:04:09 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by GreenPower Motor Company Inc. (Amendment)

    SC 13G/A - GREENPOWER MOTOR Co INC. (0001584547) (Subject)

    2/9/23 10:59:20 AM ET
    $GP
    Construction/Ag Equipment/Trucks
    Consumer Discretionary